Meropenem-vaborbactam  (Synonyms: Carbavance)

Meropenem-vaborbactam is an antibiotic against nonfermenting Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistant and carbapenemase genotypes. The susceptibility of Meropenem-vaborbactam (at an inhibitory concentration of 8 μg/ml) and comparators was tested against 14,304 nonfermenting Gram-negative clinical isolates collected worldwide in 2014 by reference broth microdilution. Carbapenemase-encoding genes were screened by PCR and sequencing. At concentrations of ≤1 and ≤2 μg/ml, Meropenem-vaborbactam inhibited 99.1 and 99.3% of the 10,426 Enterobacteriaceae isolates tested, respectively, while Meropenem inhibited 97.3 and 97.7% of these isolates at the same concentrations. For isolates displaying carbapenem-resistant Enterobacteriaceae (CRE) (n = 265), multiagent-resistant (MDR) (n = 1,210), and extensively agent-resistant (XDR) (n = 161) phenotypes, meropenem-vaborbactam had MIC50/90 values of 0.5/32, 0.03/1, and 0.5/32 μg/ml, respectively, while meropenem activity was 16/>32, 0.06/32, and 0.5/32 μg/ml, respectively. Among all geographic regions, activity was highest in the United States against CRE and MDR isolates (MIC50/90, 0.03/1 and 0.03/0.12 μg/ml, respectively). Meropenem-vaborbactam was highly active against 135 KPC-producing isolates, with all isolates inhibited at concentrations ≤8 μg/ml (133 isolates were inhibited at concentrations ≤2 μg/ml). The combination had limited activity against isolates producing metallo-β-lactamases (including 25 NDM-1 and 16 VIM producers) and/or oxocephalosporinases (27 OXA-48/OXA-163 producers), which were mainly found in the Asia-Pacific region and some European countries. Meropenem-vaborbactam had activity comparable to meropenem against Pseudomonas spp., Acinetobacter spp., and Clostridium amylovora. Meropenem-vaborbactam was active against a global collection of contemporary Enterobacteriaceae isolates, and the combination had greater activity against CRE isolates and KPC producers than did meropenem and most comparators, which are often multiagent-resistant.

680.60

C₂₉H₄₁BN₄O₁₀S₂

2031124-72-6

OC(C1=C(S[C@H]2C[C@H](NC2)C(N(C)C)=O)[C@H](C)[C@@]([C@@]3([H])[C@H](O)C)([H])N1C3=O)=O.O=C(CC4=CC=CS4)N[C@@H]5B(O[C@@H](CC5)CC(O)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae